In the animal models, this drug was given to rats that had their optic nerves severed and in the course of four weeks you could see that the optic nerve had regenerated," he said. “That’s a phenomenal thing.”
He said the drug took a different approach to Alzheimer’s, focusing on regenerating brain cells rather than reducing the beta plaque that causes the disease.
Mr Liddelow said the novel approach meant that if the drug was shown to be effective, it would have a range of applications.
“It’s potentially a disease modifier,” he said. “At the very least it will slow down the progression of the disease. The way it works, it has application across a number of neurodegenerative diseases and it could potentially treat a raft of conditions.”